Investor Presentaiton
For personal use only
ProstACT TARGET Phase II study
Expanding clinical data to include a front-line setting
PROSTACT
TARGET
Early data in front line care
Efficacy data in patients in their first recurrence
Eligible Patients
In partnership with:
GenesisCare
TELIX
PHARMACEUTICALS
•
PSMA avid (defined by TLX591-CDX)
Oligometastatic early recurrence
TLX591 + External Beam
Radiation Therapy
(EBRT)
Single arm Phase II study in Australia in 50 patients with PSMA-expressing biochemically recurrent oligometastatic
prostate cancer, in combination with external beam radiation therapy (EBRT)
To determine the efficacy, biodistribution and combination dosimetry of TLX591 plus EBRT, including dose to tumour
•
Primary endpoint: radiographic progression-free survival
•
Secondary endpoints include: overall survival, quality of life, safety
•
Status: Patient screening to commence early 2022 (subject to ethics approval)
Telix Pharmaceuticals Limited (ASX: TLX)
32
32View entire presentation